TRANSDERMAL ESTRADIOL PLUS ORAL MEDROXYPROGESTERONE ACETATE REPLACEMENT THERAPY IN PRIMARY AMENORRHEIC ADOLESCENTS - CLINICAL, HORMONAL ANDMETABOLIC ASPECTS

Twelve primary amenorrheic adolescents were treated with transdermal e stradiol 100 mu g (Estraderm TTS-100 (R)) twice weekly for 3 weeks, pl us MPA 10 mg per os daily (Provera(R)) for the last 11 days, following an interval of 1 week. A basic examination and a re-examination at 6- and 12-month intervals were carried out for clinical evaluation, horm onal assays, lipid, carbohydrate and bone metabolism. No significant c hanges were recorded on the FSH, LH, 17 beta-estradiol and PRL serum l evels. A significant decrease of TC values and atheromatic indices 1 ( TC/HDL) and 2 (LDL/HDL) was seen (P < 0.05) at the end of treatment. O n the other hand a significant increase in apolipoproteins A1 was foun d. A beneficial effect was also recorded on the bone mass. Finally, no significant side-effects were reported. It is concluded that this kin d of hormone replacement therapy is efficient and safe for the treatme nt of amenorrheic adolescents due to gonadal dysgenesis.